NDAORALTABLETPriority Review
Approved
Aug 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKEEGA is a fixed-dose combination of niraparib (a PARP inhibitor) and abiraterone acetate (an androgen synthesis inhibitor) administered as an oral tablet. This combination targets metastatic castration-resistant prostate cancer (mCRPC) by simultaneously inhibiting DNA repair and blocking androgen production. The dual mechanism addresses two critical pathways in hormone-resistant prostate cancer progression.
$0.567MPart D
Growth11.9 years to LOERecent 2023 launch in growth phase with minimal Part D penetration signals an early-stage product building commercial infrastructure and sales force capacity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer
Prostate NeoplasmsGenital Neoplasms, MaleUrogenital Neoplasms+1 more
Career Relevance
AKEEGA represents a launch-phase oncology asset from Johnson & Johnson with limited real-world job posting activity at the time of data collection, reflecting early market penetration. Career opportunities will grow as commercial scale-up accelerates and cross-functional teams (medical affairs, outcomes research, patient support) expand.
Company
Worked on AKEEGA at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.